Mayo researcher discovers target site for developing mosquito pesticides

December 20, 2006

ROCHESTER, Minn. -- A Mayo Clinic researcher has discovered a target site within malaria-carrying mosquitoes that could be used to develop pesticides that are toxic to the Anopheles gambiae mosquito and other mosquito species. It would not affect humans and other mammals. If supported by further studies, the findings could offer a safer and more effective control of mosquito-borne diseases such as malaria.

Yuan-Ping Pang, Ph.D., a chemist and expert in computer-aided molecular design at Mayo Clinic, identified two unique amino acid residues called cysteine (286) and arginine (339). These exist in three mosquito species and the German cockroach.

Dr. Pang's findings are significant because the residues could potentially be used as a target site for a pesticide that would incapacitate only insects that carry these residues, which do not exist in mammals. The findings appear in the current issue of PLoS ONE, a new, peer-reviewed, open-access journal published by the Public Library of Science.

"These findings suggest that new pesticides can be designed to target only the mosquito enzyme. Such pesticides could be used in small quantities to harm mosquitoes, but not mammals," Dr. Pang says. "We've developed a blueprint for a pesticide that could incapacitate malaria-carrying mosquitoes. We are currently making a prototype of the new pesticide."

Most pesticides today work by crippling the serine residue, which is another amino acid of the enzyme acetylcholinesterase and is located at the active site of the enzyme. This serine residue is present in both insects and mammals and therefore, any pesticide targeting this amino acid affects both insects and mammals.

Acetylcholinesterase is a vital enzyme to both insects and mammals. It breaks down the neurotransmitter acetylcholine, which is a primary neurotransmitter in the brain that is associated with memory and cognition.

Dr. Pang, director of Mayo Clinic's Computer-Aided Molecular Design Laboratory, studied the genetic makeup of all known acetylcholinesterases in 73 species, including humans. He identified residues that only exist in the mosquito version of the acetylcholinesterase. To identify which of these residues is susceptible to pesticides, he developed a three-dimensional model of mosquito acetylcholinesterase. With this three-dimensional model in hand, Dr. Pang learned how residues function in a way never before possible.

He found that the cysteine and arginine residues were located at the opening of the active site of the mosquito acetylcholinesterase. An active site is a pocket in an enzyme where a fast chemical reaction takes place to break down a molecule or build a new molecule.

Previous studies by Dr. Pang and researchers elsewhere found that the cysteine residue acts as a hook that could tether a small molecule in the active site of an enzyme and permanently damage the enzyme. This led Dr. Pang to believe the cysteine and arginine residues could be targeted by a pesticide that would not affect humans and other mammals.

"While a three-dimensional model of the mosquito enzyme acetylcholinesterase has been reported by other scientists, no mosquito-specific residue at the active site of acetylcholinesterase has been reported until now," Dr. Pang says. "These findings suggest that a chemically stable molecule (to be used as a safer pesticide) could be made to react with the cysteine residue in the mosquito enzyme acetylcholinesterase and irreversibly inhibit the enzyme."

The three-dimensional model Dr. Pang developed was created with a powerful computing system called a terascale system. He built the system with 590 personal computers. Terascale refers to computational power measured in the unit of teraflops, which is a processor capable of a speed of one trillion floating-point operations per second. A single teraflops computer is comparable to a computer that can search at least 50,000 Manhattan phonebooks in one second. Terascale systems are among the most powerful computers available today.

Dr. Pang published similar findings in October 2006 in which he described a potentially safer and more effective method for controlling crop-destroying aphids. The study was published in the journal Bioorganic & Medicinal Chemistry Letters.

Background on pesticides and malaria

DDT has been banned in most parts of the world for decades, but approximately 20 countries currently use the pesticide to control malaria and others are considering its use. DDT use remains controversial, as some studies have linked its use to environmental and health problems. Still, it is largely believed to be among the most effective methods to kill malaria-carrying mosquitoes.

Malaria continues to be the leading cause of death and morbidity in poor countries, according to the World Health Organization (WHO). More than one million deaths and up to 500 million clinical cases are reported each year. Most of the 3,000 deaths that occur each day worldwide are of children in Africa. More than one-third of the world's population lives in malaria-endemic areas. According to a 2006 report by the Centers for Disease Control and Prevention, there were outbreaks of locally acquired mosquito-transmitted malaria in the United States.
-end-
The research funding for Dr. Pang's study was provided by Mayo Clinic.

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

Mayo Clinic

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.